Literature DB >> 35399108

Global variations in preoperative practices concerning patients seeking primary bariatric and metabolic surgery (PACT Study): A survey of 634 bariatric healthcare professionals.

Wah Yang1,2,3, Sally Abbott4,5, Cynthia-Michelle Borg6, Paul Chesworth7, Yitka Graham8,9,10, Jennifer Logue11, Jane Ogden12, Mary O'Kane13, Denise Ratcliffe14, Shiri Sherf-Dagan15,16, Rishi Singhal17,18, Vanessa Snowdon-Carr19, Abd Tahrani20,21,22, Kamal Mahawar8,10.   

Abstract

BACKGROUND: Bariatric and Metabolic Surgery (BMS) is a popular weight loss intervention worldwide, yet few scientific studies have examined variations in preoperative practices globally. This study aimed to capture global variations in preoperative practices concerning patients planned for BMS.
METHODS: A 41-item questionnaire-based survey was designed and the survey link was freely distributed on social and scientific media platforms, email groups and circulated through personal connections of authors. The survey included eight parts: basic information; criteria for BMS; preoperative nutritional screening; preoperative weight loss; preoperative diets for liver size reduction; preoperative glycemic control; other laboratory investigations and preparations; decision making, education, and consents. Descriptive statistics were used to analyse data and graphs were used for representation where applicable.
RESULTS: Six hundred thirty-four bariatric healthcare professionals from 76 countries/regions completed the survey. Of these, n = 310 (48.9%) were from public hospitals, n = 466 (73.5%) were surgeons, and the rest were multidisciplinary professionals. More than half of respondents reported using local society/association guidelines in their practice (n = 310, 61.6%). The great majority of respondents routinely recommend nutritional screening preoperatively (n = 385, 77.5%), mandatory preoperative diets for liver size reduction (n = 220, 53.1%), routine screening for T2DM (n = 371, 90.7%), and mandate a glycemic control target before BMS in patients with T2DM (n = 203, 55.6%). However, less than half (n = 183, 43.9%) recommend mandatory preoperative weight loss to all patients. Most respondents (n = 296, 77.1%) recommend psychological intervention before surgery for patients diagnosed with psychological conditions. Variations were also identified in laboratory investigations and optimisation; and in the aspects of decision making, education and consent.
CONCLUSIONS: This survey identified significant global variations in preoperative practices concerning patients seeking primary BMS. Our findings could facilitate future research for the determination of best practice in these areas of variations, and consensus-building to guide clinical practice while we wait for that evidence to emerge.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 35399108     DOI: 10.1038/s41366-022-01119-x

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.551


  1 in total

Review 1.  British Obesity and Metabolic Surgery Society Guidelines on perioperative and postoperative biochemical monitoring and micronutrient replacement for patients undergoing bariatric surgery-2020 update.

Authors:  Mary O'Kane; Helen M Parretti; Jonathan Pinkney; Richard Welbourn; Carly A Hughes; Jessica Mok; Nerissa Walker; Denise Thomas; Jennifer Devin; Karen D Coulman; Gail Pinnock; Rachel L Batterham; Kamal K Mahawar; Manisha Sharma; Alex I Blakemore; Iris McMillan; Julian H Barth
Journal:  Obes Rev       Date:  2020-08-02       Impact factor: 9.213

  1 in total
  1 in total

1.  The Aftermath of Bariatric Surgery: Can the Average Emergency Surgeon Deal with Its Complications? Comment on Zawadzka et al. Current Knowledge and Perceptions of Bariatric Surgery among Diabetologists and Internists in Poland. J. Clin. Med. 2022, 11, 2028.

Authors:  Chrysanthi Papageorgopoulou; Konstantinos Nikolakopoulos; Charalampos Seretis
Journal:  J Clin Med       Date:  2022-06-14       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.